

Informing fresh versus standard Issue red cell management

Submission date 23/11/2011	Recruitment status No longer recruiting	☒ Prospectively registered ☒ Protocol
Registration date 16/02/2012	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 01/03/2019	Condition category Haematological Disorders	☐ Individual participant data

Plain English summary of protocol

Background and study aims

Transfusion of red blood cells is life-saving, but recent data suggests that transfusion of stored blood may also cause some harm. Transfusion of red blood cells stored for up to 42 days is standard medical practice. Recent studies have suggested the changes that develop during red blood cell storage might contribute to increased risk in some patients, but the results have generated significant controversy. In order to resolve the controversy, several studies are currently underway in very specific patient populations (critical care patients, patients undergoing cardiac surgery) comparing very fresh blood (less than 8 to 10 days of storage, with standard issue blood. This study will include all hospital patients receiving transfusion and does not use a specific storage age to define fresh blood; hence, it will provide information that will apply to all transfused patients. This study aims to determine the effect on in-hospital death rates of transfusing the freshest available blood compared with standard-issue blood.

Who can participate?

All adults (18 years of age or older) patients admitted to the hospital who will receive a transfusion during their stay are potentially eligible for the study.

What does this study involve?

The participant will not be contacted during this study. The decision to transfuse is determined by the patient's doctor. Once the ward orders the blood, the Transfusion Medicine Service will randomly allocate the patient to receive either the freshest available or standard-issue blood. The patient's data will be collected electronically. An information brochure will be distributed to the patient so they are made aware of the study.

What are the possible benefits and risks of participating?

As of yet, there are no direct known benefits for the participating patients. Future societal benefits may occur from this study depending on the study findings. There are no added risks of participating in this study. The decision to transfuse a patient happens independently of the study.

Where is the study run from?

The study is run from the McMaster Transfusion Medicine Program at McMaster University in

Hamilton, Canada. Patients are recruited from Hamilton General Hospital (Canada), Juravinski Hospital (Canada), Flinders Medical Centre (Australia), St Joseph's Healthcare in Hamilton (Canada) and the Cleveland Clinic (USA).

When is the study starting and how long is it expected to run for?
January 2012 to November 2015

Who is funding the study?
Canadian Institutes of Health Research (CIHR) (Canada)

Who is the main contact?
Rebecca Barty
bartyr@mcmaster.ca

Contact information

Type(s)
Scientific

Contact name
Ms Rebecca Barty

Contact details
Clinical Research Coordinator
McMaster Transfusion Research Program
McMaster University Faculty of Health Sciences Department of Medicine
HSC-3H50
1280 Main Street West
Hamilton
Canada
L8S 4K1
+1 (0)905 525 9140 ext. 22945
bartyr@mcmaster.ca

Type(s)
Scientific

Contact name
Dr John Eikelboom

Contact details
Department of Medicine
Hematology +Thromboembolism
HHSC, Hamilton General Hospital
Hamilton
Canada
L8L 2X2
+1 (0)905 521 2100 x44768
eikelbj@mcmaster.ca

Additional identifiers

Protocol serial number

Sept122011

Study information

Scientific Title

INforming Fresh versus Old Red cell Management (INFORM): a large simple phase III randomized controlled trial

Acronym

INFORM

Study objectives

The freshest available compared with standard-issue blood reduces mortality.

Pilot study registered under ISRCTN38768001.

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Hamilton Health Sciences/Faculty of Health Sciences, Research Ethics Board, 16/08/2011
2. Southern Adelaide Clinical Human Research Ethics Committee, 15/08/2011
3. Cleveland Clinic, Institutional Review Board, 11/06/2012
4. St Joseph's Healthcare, Research Ethics Board, 17/05/2012

Primary study design

Interventional

Study design

Multi-centre international randomized controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Red blood cell transfusion

Interventions

Patients requiring red blood cell transfusion will be randomized to one of the following conditions:

1. Freshest available red blood cells (experiment arm)
2. Standard-issue (oldest product compatible in stock) red blood cells available (control arm)

Both arms (experiment and control) are within standard care

The participant will not be contacted during this study. The decision to transfuse is determined by the patient's doctor. Once the ward orders the blood, the Transfusion Medicine Service will randomly allocate the patient to receive either the freshest available or standard-issue blood.

The patient's data will be collected electronically. An information brochure will be distributed to the patient so they are made aware of the study.

Intervention Type

Biological/Vaccine

Phase

Phase III

Primary outcome(s)

In-hospital mortality

Key secondary outcome(s)

Time to event (death)

Completion date

20/11/2015

Eligibility**Key inclusion criteria**

All adult patients (age ≥ 18) will be included if:

1. Hospitalized at a participating centre (in-patient)
2. Undergoing a red cell transfusion

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Key exclusion criteria

1. Specific requirement for fresh blood (e.g., sickle cell disease, transfusion-dependent thalassemia, fresh cells ordered by care provider)
2. Pre-planned directed or autologous donation
3. Request for un-crossmatched blood
4. Anticipated massive transfusion as communicated from clinical area

Date of first enrolment

02/04/2012

Date of final enrolment

30/09/2015

Locations

Countries of recruitment

Australia

Canada

Israel

United States of America

Study participating centre

Hamilton General Hospital

Canada

-

Study participating centre

Juravinski Hospital

Canada

-

Study participating centre

Flinders Medical Centre

Australia

-

Study participating centre

St Joseph's Healthcare Hamilton

Canada

-

Study participating centre

Cleveland Clinic

United States of America

-

Study participating centre
Meir Medical Center
Israel
-

Sponsor information

Organisation
McMaster University (Canada)

ROR
<https://ror.org/02fa3aq29>

Funder(s)

Funder type
Government

Funder Name
Canadian Institutes of Health Research (CIHR) (Canada)

Alternative Name(s)
Instituts de Recherche en Santé du Canada, The Canadian Institutes of Health Research (CIHR), Canadian Institutes of Health Research (CIHR), Canadian Institutes of Health Research | Ottawa ON, CIHR - Welcome to the Canadian Institutes of Health Research, CIHR, IRSC

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
Canada

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	17/11/2016		Yes	No
Protocol article	protocol	01/01/2016		Yes	No
Other publications	secondary analysis	01/11/2017		Yes	No